ISRCTN ISRCTN16378480
DOI https://doi.org/10.1186/ISRCTN16378480
Submission date
27/04/2022
Registration date
12/05/2022
Last edited
29/05/2024
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Background and study aims
The HRH2030 program and the University of Malawi will study the effect of using a mental health chatbot named ‘Vitalk’ on the mental wellbeing of health workers. The aim of this study is to test whether the use of Vitalk over a period of eight weeks leads to better mental health outcomes. To achieve the this aim we will compare changes in mental wellbeing in a group that uses Vitalk with the changes in another group that has access to websites about mental health. We will measure mental wellbeing asking study participants to complete commonly used test for depression, anxiety, resilience, burnout, and loneliness. In addition, we are interested in measuring how active study participants are in building their resilience in coping with daily challenges in their work and personal life, which includes activities for managing stress, raising self-awareness, performing self-care, finding purpose, and connecting with others.

Who can participate?
Health workers in Malawi.

What does the study involve?
Participants will be asked to take the mental health tests three times throughout the study period. Participants using Vitalk interact daily with the mobile phone app, which guides health workers through exercises that can increase self-awareness and provides them with self-help and coping tips. Participants that have access to websites about mental wellbeing but not to Vitalk can use these on their initiative; this group is self-directed and does not have an interactive element.

What are the possible benefits and risks of participating?
The expected benefit of the study is a greater attention to work-related stress that healthcare providers face especially during the COVID-19 pandemic of 2020/21, which overwhelmed countries’ health systems and increased care-related pressure in the effort of ensuring patient care and staff safety.

Where is the study run from?
University of Malawi

When is the study starting and how long is it expected to run for?
July 2021 to February 2022

Who is funding the study?
United States Agency for International Development (USA)

Who is the main contact?
Ekhard Kleinau, ekleinau@urc-chs.com
Katy Gorentz, kgorentz@chemonics.com

Contact information

Dr Eckhard Kleinau
Principal Investigator

5404 Wisconsin Ave
Suite 800
Chevy Chase, MD
20815
United States of America

ORCiD logoORCID ID 0000-0003-0304-1644
Phone +1 3016548338
Email ekleinau@urc-chs.com
Dr Eckhard Kleinau
Scientific

5404 Wisconsin Ave
Suite 800
Chevy Chase, MD
20815
United States of America

Phone +1 3016548338
Email ekleinau@urc-chs.com
Ms Katy Gorentz
Public

Chemonics International
1275 New Jersey Avenue SE
Suite 200
Washington, DC
20003-5115
United States of America

Phone +1 8889556881
Email kgorentz@chemonics.com

Study information

Study designInterventional randomized controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Internet/virtual
Study typeQuality of life
Participant information sheet 41650 PIS.pdf
Scientific titleEffectiveness of a chatbot in improving the mental wellbeing of health workers in Malawi during the COVID-19 pandemic: A randomized, controlled trial
Study acronymHRH2030-Vitalk
Study hypothesisThe use of a chatbot such as Vitalk over a period of eight weeks results in different mental health outcomes in a treatment and control group of health workers in Malawi.
Ethics approval(s)Approved 08/10/2021, University Research Co., LLC IRB (5404 Wisconsin Ave., Ste 800 Chevy Chase, MD 20815-3594, USA; +1 301-654-8338; bturesson@URC-CHS.COM)
ConditionMental health outcomes (including depression, anxiety, burnout, loneliness, and resilience) among health workers in Malawi
InterventionThe study is a two-arm, parallel randomized controlled trial with a pre-treatment assessment, 8-week intervention period and mid-study assessments at 4-5 weeks and an end-of-study assessment at 9 weeks. Interested study participants will be randomly assigned to either the treatment or control group at the time of registration. Vitalk, the developer of the app, will create a study web portal where study participants register, give their consent, are assigned to one of the study arms, are given a unique study identification number, and enter their demographic information. Depending on the random assignment, participants will be taken to either the treatment app, Vitalk, or the website for the control group. This is a single-blinded design because only the research team will be blinded to the study arm assignments; all participants in both study arms will be told they are participating in ‘an online self-help for mental wellbeing’.
Originating from Brazil, Vitalk is an automated chatbot delivering mental health content to its users using a conversational format, with the aim of improving well-being by reducing stress, anxiety and depression using a preventative approach to mental health (Daley, Hungerbuehler et al., 2020). The Vitalk app uses psychoeducation, cognitive restructuring, behavioral activation, gratitude, and practical exercises (such as breathing, relaxation and meditation) to bring about improvements in users’ mental health (ibid). These techniques and strategies are rooted in CBT and Positive Psychology, two commonly used psychotherapy methodologies that have been used widely in various settings and have registered high effectiveness among patients presenting with various psychological challenges (Beck, 2011; Seligman, 1998; Wills, 2009). Only the treatment arm of the study will have access to Vitalk. The control arm of the study will have access to a website with links to mental health resources from WHO and other self-help providers as well as contact information for psychologists and mental health counselors in Malawi. This website consists of a few pages with basic mental health and coping information, links to mental wellbeing resources, mood meter and standardized mental health tests. Its content is static without user interaction beyond clicks to access web-based mental health resources. Whether or not these resources are used depends entirely on the initiative of control group participants.
Intervention typeBehavioural
Primary outcome measureMeasurements at baseline, 4-5 weeks, and 9 weeks:
1. Anxiety symptoms are measured using the Generalized Anxiety Disorder (GAD-7) scale.
2. Depression symptoms are measured using the Patient Health Questionnaire (PHQ-9).
3. Burnout is measured using the Oldenburg Burnout Inventory (OLBI).
4. Loneliness is measured using the UCLA Short Loneliness Scale.
5. Resilience is measured using the 14-item Resilience Scale (RS-14).
Secondary outcome measures1. Resilience building behaviors measured through questionnaires in Vitalk at baseline, 4-5 weeks, and 9 weeks
2. Frequency and use of treatment app and control website, measured throughout the trial through app and website usage data
3. Qualitative patient experiences measured using an anonymous online survey at 9 weeks
Overall study start date01/07/2021
Overall study end date08/02/2022

Eligibility

Participant type(s)Health professional
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants1280
Total final enrolment1584
Participant inclusion criteria1. Currently employed as one of the types of service providers (cadres) listed: doctors, nurses, medical assistants, clinical officers, laboratory technicians, physiotherapy technicians, pharmacists, physiotherapists
2. Employed in public or private primary, secondary, or tertiary care facility in Blantyre and Lilongwe districts of Malawi
3. Possess some degree of English language proficiency
4. Own a smartphone with an Android operating system
5. No history – past or current – of counseling or therapy for severe mental health disorders
6. Not have self-reported suicidal ideation
7. Score below “very high risk” levels on the initial assessments for anxiety and depression
8. Diploma in their respective fields of specialization, in adherence to the Ministry of Health employment criteria for the respective cadres of health workers (Medical Assistants who completed 2 years of college will be allowed to participate even though their qualification is a certificate)
9. Adults (18 years or older)
Participant exclusion criteria1. All other hospital- or health-related personnel, such as health surveillance assistants, hospital assistants or laboratory assistants, due to their lower educational qualification requirement for employment.
2. Health workers with a history – past or current – of counseling or therapy for a severe mental disorder
3. All study applicants at “very high risk” of depression and anxiety according to their initial scores from standard mental health tests
4. Participants who check suicidal ideation in question nine of the PHQ-9
Recruitment start date18/10/2021
Recruitment end date19/11/2021

Locations

Countries of recruitment

  • Malawi

Study participating centres

Malawi University of Business and Applied Sciences
Private Bag 303
Chichiri
Blantyre
N/A
Malawi
Kamuzu University of Health Sciences – Kamuzu College of Nursing
Private Bag 1
Lilongwe
N/A
Malawi

Sponsor information

Chemonics International
Other

1275 New Jersey Avenue SE
Suite 200
Washington, DC
20003-5115
United States of America

Phone +1 8889556881
Email info@HRH2030Program.org
Website https://www.chemonics.com/

Funders

Funder type

Government

United States Agency for International Development
Government organisation / National government
Alternative name(s)
U.S. Agency for International Development, Agency for International Development, USAID
Location
United States of America

Results and Publications

Intention to publish date30/09/2023
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryStored in publicly available repository
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planThe datasets generated during and/or analyzed during the study will be made available to the public through the USAID Development Data Library database (DDL, https://data.usaid.gov/). Data will be anonymized and made available to the public following the data privacy measures established in the protocol and communicated to participants in the informed consent process. The data will be submitted to the database following publication and will be publicly available upon review and acceptance by the USAID DDL. The dataset will include anonymized data on responses to mental wellbeing questions, data on app or website usage, and limited personal data (e.g. health worker cadre).

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Participant information sheet 09/05/2022 No Yes
Protocol file 09/05/2022 No No
Other files 02/02/2023 No No
Results article 28/05/2024 29/05/2024 Yes No

Additional files

41650 Protocol.pdf
41650 PIS.pdf
ISRCTN16378480_TREND_checklist.pdf

Editorial Notes

29/05/2024: Publication reference added.
02/02/2023: TREND checklist uploaded as an additional file.
24/01/2023: The intention to publish date was changed from 19/11/2022 to 30/09/2023.
09/05/2022: Trial's existence confirmed by University Research Co LLC.